FDA extends Benlysta PDUFA target date: HGS, GSK
Belimumab is an investigational drug and the first in a new class of drugs called BLyS-specific inhibitors. After the FDA Arthritis Advisory Committee met on November 16, 2010
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The single-arm pivotal trial assessed efficacy and safety of single-agent brentuximab vedotin in relapsed or refractory, post-autologous stem cell transplant (ASCT) Hodgkin lymphoma patients. Brentuximab vedotin is an
rFVIIIFc is a fully-recombinant clotting factor developed using Biogen Idec‘s novel and proprietary monomeric Fc fusion technology. The technology makes use of a natural mechanism that recycles rFVIIIFc